Need a specific person's email?
Browse Promontory Therapeutics's employee directory (about 11 employees) and reveal verified emails free.
Promontory Therapeutics's most common email format is FLast@phosplatin.com (ex. JDoe@phosplatin.com), used for 94% of phosplatin.com addresses. Promontory Therapeutics uses 3 email patterns across 2 domains: phosplatin.com and promontorytx.com. Percentages are the share of addresses within each domain.
| Format | Example | Share of phosplatin.com |
|---|---|---|
| FLast@phosplatin.comMost common | JDoe@phosplatin.com | |
| Last@phosplatin.com | Doe@phosplatin.com |
| Format | Example | Share of promontorytx.com |
|---|---|---|
| FLast@promontorytx.comMost common | JDoe@promontorytx.com |
Browse Promontory Therapeutics's employee directory (about 11 employees) and reveal verified emails free.
Biotechnology ResearchNew York, United States11-50 Employees
Promontory Therapeutics is a private, clinical-stage biopharmaceutical company based in New York City, founded in 2010. It holds exclusive global rights to phosphaplatins, a family of novel agents in development for solid tumors and hematologic cancers. These compounds are designed to engage an immunogenic form of apoptosis while maintaining a favorable safety profile, and the lead candidate, PT-112, is supported by two FDA-approved IND applications. In 2023, the company expanded its clinical presence to France, signaling an effort to broaden its development footprint. Operating in the biotechnology research sector, Promontory focuses on immunogenic small molecule approaches in oncology and advances PT-112 through its ongoing clinical program.
Most common format
FLast@phosplatin.com
Example: JDoe@phosplatin.com
Free with a LeadIQ account. No credit card.
Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.